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Introduction
Five species of  Plasmodium parasite are known to cause malaria following human infection, with P. falci-
parum the major causative agent of  deaths in sub-Saharan Africa and thus historically the dominant focus of  
vaccine development efforts (1). However, a second parasite species, P. vivax, is more widespread geographi-
cally and also constitutes a significant proportion of  human malaria cases. Indeed, recent data suggest 2.5 
BACKGROUND. Plasmodium vivax is the most widespread human malaria geographically; 
however, no efective vaccine exists. Red blood cell invasion by the P. vivax merozoite depends 
on an interaction between the Dufy antigen receptor for chemokines (DARC) and region II of the 
parasite’s Dufy-binding protein (PvDBP_RII). Naturally acquired binding-inhibitory antibodies 
against this interaction associate with clinical immunity, but it is unknown whether these responses 
can be induced by human vaccination.
METHODS. Safety and immunogenicity of replication-deicient chimpanzee adenovirus serotype 
63 (ChAd63) and modiied vaccinia virus Ankara (MVA) viral vectored vaccines targeting PvDBP_RII 
(Salvador I strain) were assessed in an open-label dose-escalation phase Ia study in 24 healthy UK 
adults. Vaccines were delivered by the intramuscular route in a ChAd63-MVA heterologous prime-
boost regimen using an 8-week interval.
RESULTS. Both vaccines were well tolerated and demonstrated a favorable safety proile in 
malaria-naive adults. PvDBP_RII–speciic ex-vivo IFN-Ȗ T cell, antibody-secreting cell, memory B 
cell, and serum IgG responses were observed after the MVA boost immunization. Vaccine-induced 
antibodies inhibited the binding of vaccine homologous and heterologous variants of recombinant 
PvDBP_RII to the DARC receptor, with median 50% binding-inhibition titers greater than 1:100.
CONCLUSION. We have demonstrated for the irst time to our knowledge that strain-transcending 
antibodies can be induced against the PvDBP_RII antigen by vaccination in humans. These vaccine 
candidates warrant further clinical evaluation of eicacy against the blood-stage P. vivax parasite.
TRIAL REGISTRATION. Clinicaltrials.gov NCT01816113.
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billion people are living at risk of  P. vivax infection in the Americas, Central and Southeast Asia (2), as well 
as Africa (3), highlighting significant levels of  morbidity that have been chronically underappreciated (4). 
Consequently, the revised Malaria Vaccine Technology Roadmap to 2030 (5) now recognizes the importance 
of  P. vivax and calls for a vaccine to achieve 75% efficacy over 2 years — equally weighted with P. falciparum 
in an era of  renewed political will to move towards malaria elimination and eradication.
Different vaccine strategies target different stages of  the malaria parasite’s complex life cycle. To date, 
2 subunit vaccines targeting the pre-erythrocytic stage P. vivax circumsporozoite protein (PvCSP), based on 
recombinant protein- or long synthetic peptide–in-adjuvant formulations, have reached clinical trials (6, 7). 
The soluble recombinant protein candidate, VMP001, delivered in GlaxoSmithKline’s (GSK’s) proprietary 
Adjuvant System AS01B, showed robust immunogenicity in healthy US volunteers but failed to induce sterile 
protection following P. vivax controlled human malaria infection (CHMI) using a mosquito bite protocol; 
however, a small but significant delay in time to parasitemia was seen in 16 of  27 vaccinated subjects com-
pared with the control group (7). A virus-like particle (VLP) using the same antigen fused to hepatitis B surface 
antigen (HBsAg), expressed in Saccharomyces cerevisiae and designated CSV-S,S, showed modest improvements 
in immunogenicity when tested in rhesus macaques with AS01 (8), but has not progressed to clinical testing. 
In 2 other phase Ia clinical trials, a soluble recombinant protein vaccine targeting the sexual-stage ookinete 
surface protein Pvs25 was tested in 2 different adjuvants. This vaccine candidate, called Pvs25H, showed 
transmission-blocking activity in a direct membrane feeding assay when formulated with Alhydrogel (9), but 
vaccinations with Montanide ISA 51 were halted due to unexpected reactogenicity (10). None of  these pre-
erythrocytic or transmission-blocking candidate subunit vaccines remain in active clinical development.
Vaccines targeting the asexual blood-stage infection form an alternative and complementary approach to 
vaccines against the other life cycle stages, seeking to control and clear parasitemia in order to prevent clini-
cal disease and death as well as onward transmission. Although many candidates have been assessed over 
the years for P. falciparum (1), no clinical trials of  vaccines against merozoite ligands involved in erythrocyte 
invasion have been reported for P. vivax (11). The Duffy-binding proteins (DBPs), or erythrocyte-binding 
ligands/antigens (EBL/EBA), are a family of  micronemal parasite proteins that are functionally conserved 
across Plasmodium species. All parasites have at least one EBL, and in many cases these lead to redundancy, 
as has been well established in P. falciparum (12). However in the case of  P. vivax, invasion of  host red blood 
cells (RBC) is restricted to CD71+ reticulocytes (13) and believed to necessitate the interaction of  the P. 
vivax Duffy-binding protein (PvDBP) with the human Duffy antigen receptor for chemokines (DARC/Fy) 
(14). Notably, Duffy-negative individuals are protected from blood-stage P. vivax infection, an observation 
first reported by Miller et al. in 1976 (15), confirmed by CHMI studies (16), and associated geographically 
with low-level endemicity in sub-Saharan Africa (3). Consistent with this, genetic knockout of  the ortholo-
gous simian malaria P. knowlesi DBPĮ gene also prevents invasion of  Duffy-positive erythrocytes in vitro 
(17). However, this paradigm of  an essential RBC invasion pathway has been challenged in recent years 
with reports of  P. vivax infection in Duffy-negative individuals (3, 18) and a growing appreciation of  the 
complexity of  other families of  invasion ligands, such as the reticulocyte-binding proteins (PvRBPs) (19). 
In parallel, a PvDBP gene duplication in P. vivax isolates (20) has also been reported, likely representing a 
second erythrocyte-binding protein (EBP2) (21), although studies have not linked this gene to Duffy-negative 
infection (22, 23). Therefore, although the complete molecular basis of  P. vivax invasion into DARC-negative 
erythrocytes remains unknown, it may still involve PvDBP.
In the case of  PvDBP, a conserved, extracellular, cysteine-rich region known as region II (PvDBP_
RII) contains the receptor-binding domain of  PvDBP. Structural analyses of  this domain have shown that 
PvDBP_RII dimers bind either 1 or 2 DARC ectodomains, creating distinct heterotrimeric and heterotetra-
meric architectures (24, 25). Immunization of  mice, rabbits, and nonhuman primates (NHPs) using PvDBP_
RII–based vaccines induces binding-inhibitory antibodies (BIAbs) (26–28), and those raised against the P. 
knowlesi DBPĮ ortholog can block RBC invasion by this parasite in vitro (29). In humans, naturally acquired 
high-titer BIAbs against PvDBP_RII have been associated with reduced risk of  P. vivax infection, lower P. 
vivax parasite densities following infection, and decreased risk of  clinical malaria (30, 31). Consequently, 
PvDBP_RII remains the most promising subunit vaccine target against P. vivax merozoites; however, this 
antigen has never progressed to clinical trials and no data are available on the ability of  vaccines to induce 
effective immune responses in humans.
With regard to antibody induction by vaccination, the mainstay approach has been the development of  
recombinant protein- or VLP-in-adjuvant formulations. An alternative strategy has used recombinant viral 
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vectored vaccines to deliver protein antigens of interest with the key aim of inducing antibodies in conjunction 
with T cell responses. The most successful approach to date has utilized a recombinant replication-deficient 
adenovirus (of human or simian serotype) to prime the immune response, followed by a booster vaccination 
(typically 8 weeks later) with an attenuated poxvirus recombinant for the same antigen (32). These vectors have 
shown high-titer antibody induction against numerous difficult-to-express malaria antigens in animal models, 
including NHPs (33, 34). We, and others, have previously reported such viral vectored vaccines to be safe and 
immunogenic for T cells and antibodies in healthy adult UK and US volunteers when delivering numerous 
P. falciparum antigens, including the pre-erythrocytic antigen multiple-epitope string fused to thrombospondin-
related adhesion protein (ME-TRAP) (35) and circumsporozoite protein (PfCSP) (36), as well as the blood-stage 
antigens merozoite surface protein 1 (PfMSP1) (37) and apical membrane antigen 1 (PfAMA1) (38, 39). In 2014 
and 2015, the same adenovirus-poxvirus vectored vaccine technologies were developed rapidly for Ebola (40).
Here, we report the safety and immunogenicity of  a similar approach in an open-label dose-escalation 
phase Ia study in healthy UK adults using replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) 
and the attenuated orthopoxvirus modified vaccinia virus Ankara (MVA) encoding PvDBP_RII from the 
Salvador I (SalI) reference strain of  P. vivax. These vaccines have been previously shown to be immunogenic 
in mice and rabbits (27). Now we show that these vaccines demonstrate a favorable safety profile in malaria-
naive adults, and confirm to our knowledge for the first time that substantial PvDBP_RII–specific antibodies 
and B cell and T cell responses can be induced by immunization in humans. Vaccine-induced serum anti-
bodies were capable of  inhibiting the in vitro binding of  vaccine homologous and heterologous variants of  
recombinant PvDBP_RII to the DARC receptor.
Results
Twenty-four healthy adult volunteers were enrolled into the VAC051 trial to test the ChAd63-MVA PvDBP_RII vaccine 
in an open-label, dose-escalation study design. Thirty UK adult volunteers were screened in total, of  which 24 
were enrolled (Figure 1). Four volunteers were recruited to groups 1 and 2A, and 8 volunteers to groups 
2B and 2C. In total, 15 females and 9 males were enrolled. The mean age of  volunteers was 25 years 9 
months (range 18–40 years). Four volunteers were enrolled into group 1 and received 5 × 109 viral particles 
(vp) of  the ChAd63 PvDBP_RII vaccine. Following a safety review, the dose of  ChAd63 PvDBP_RII was 
increased to 5 × 1010 vp for group 2. Four volunteers in group 2A received ChAd63 PvDBP_RII alone, 
while volunteers in groups 2B and 2C received ChAd63 PvDBP_RII followed 8 weeks later with a boost 
vaccination of  MVA PvDBP_RII at a dose of  1 × 108 plaque-forming units (PFU) or 2 × 108 PFU, respec-
tively. One volunteer withdrew from group 2B prior to the MVA PvDBP_RII vaccination due to personal 
commitments and was not replaced, resulting in 23 volunteers completing follow-up as per protocol.
ChAd63 and MVA PvDBP_RII show a favorable safety profile in healthy UK adult volunteers. There were 
no serious adverse events (AEs) or unexpected reactions during the course of  the trial and no volunteers 
withdrew due to vaccine-related AEs. ChAd63 PvDBP_RII and MVA PvDBP_RII demonstrated favorable 
safety profiles, similar to those seen in previous clinical trials with the same viral vectors recombinant for P. 
falciparum malaria antigens (35–38). All AEs following ChAd63 PvDBP_RII 5 × 109 vp were mild, as were 
the vast majority in group 2, although some volunteers did report moderate or severe AEs following immu-
nization with the full dose. The higher dose of  MVA PvDBP_RII was more reactogenic than the lower 
dose, with half  of  the volunteers reporting at least 1 severe AE, although no systemic AE was reported as 
severe for more than 24 hours. The maximum severities of  solicited local and systemic AEs reported by 
volunteers following each vaccination are shown in Figure 2. All unsolicited AEs considered possibly, prob-
ably, or definitely related to either vaccination were mild in nature (Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.93683DS1). There was only 
1 laboratory AE following ChAd63 PvDBP_RII that was considered possibly, probably, or definitely relat-
ed to vaccination: a mild lymphopenia in 1 volunteer vaccinated with 5 × 1010 vp. Similarly, there was only 
1 laboratory AE following MVA PvDBP_RII that was considered possibly, probably, or definitely related to 
vaccination: a moderate eosinophilia in 1 volunteer vaccinated with 1 × 108 PFU, which peaked more than 
4 weeks after vaccination. Both of  these laboratory AEs resolved spontaneously.
ChAd63 and MVA PvDBP_RII expand IFN-Ȗ T cell responses in healthy UK adult volunteers. The kinetics and 
magnitude of  the PvDBP-specific T cell response were assessed over time by ex vivo IFN-Ȗ ELISPOT fol-
lowing restimulation of  peripheral blood mononuclear cells (PBMCs) with 20-mer peptides overlapping by 
10 amino acids (aa) spanning the entire PvDBP_RII insert present in the vaccines (Figure 3). Vaccination 
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with ChAd63-MVA PvDBP_RII induced antigen-specific T cell responses in all volunteers, with individual 
responses shown in Supplemental Figure 1 and median responses to the total vaccine insert shown for each 
group in Figure 3A. Following ChAd63 PvDBP_RII prime, there was no significant difference between 
median responses in the lower-dose group 1 in comparison with group 2 at the peak of  the response on 
day 14 (median 787 [range 140–1,893] vs. 937 [range 96–4,141] spot-forming units [SFU]/million PBMCs 
in groups 1 versus 2, respectively; n = 4 vs. 20, P = 0.79 by Mann-Whitney test) (Figure 3B). Responses 
subsequently followed classical T cell kinetics and contracted by day 56 (Figure 3A). Administration of  
MVA PvDBP_RII significantly boosted these responses in all volunteers as measured 1 week later on day 
63 (groups 2B and 2C vs. 2A, Kruskal-Wallis test with Dunn’s multiple comparison test) (Figure 3C), reach-
ing medians of  2,061 (range 1,232–2,844) and 2,459 (range 675–4,336) SFU/million PBMCs in groups 2B 
and 2C, respectively, versus 368 (range 127–699) SFU/million PBMCs in group 2A. However, there was no 
significant difference between the 2 groups who received the different doses of  MVA PvDBP_RII (P = 0.96, 
Mann-Whitney test). T cell responses were spread across the whole PvDBP_RII antigen, with responses 
Figure 1. VAC051 flow chart of study design and volunteer recruitment. Recruitment for the VAC051 study took place between May 2013 and Febru-
ary 2014. The inal follow-up visit took place in July 2014. All immunizations were administered intramuscularly, with sequential vaccines adminis-
tered into the deltoid of alternating arms.
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detected in all 6 of  the peptide pools used in the ELISPOT assay (Supplemental Figure 2). Following the 
peak at day 63, responses contracted but were maintained above baseline at the end of  the study period, with 
significantly better maintained responses at day 140 in group 2C as compared with group 2B (median 1,871 
vs. 385 SFU/million PBMCs) (P = 0.03, Mann-Whitney test) (Figure 3D).
ChAd63 and MVA PvDBP_RII induce serum antibody responses and memory B cells in healthy UK adult vol-
unteers. The kinetics and magnitude of  the anti–PvDBP_RII serum IgG antibody response were assessed 
over time by ELISA against recombinant protein (Figure 4). Priming vaccination with 5 × 1010 vp ChAd63 
PvDBP_RII followed by MVA PvDBP_RII boost induced antigen-specific IgG responses in all volunteers 
(groups 2B and 2C), with individual responses shown in Supplemental Figure 3 and median responses 
shown for each group in Figure 4A. Responses are reported in ȝg/ml following conversion of  ELISA 
arbitrary units (AU) by calibration-free concentration analysis (CFCA) (Supplemental Figure 4). Follow-
ing ChAd63 PvDBP_RII prime with 5 × 109 vp, none of  the 4 volunteers showed a detectable response 
on day 28, in contrast to 12 of  20 volunteers who did show a response (median 0.3, range 0–2.3 ȝg/ml, 
n = 20) following priming with 5 × 1010 vp (P = 0.07, Mann-Whitney test) (Figure 4B). Responses were 
subsequently maintained in group 2 volunteers prior to administration of  MVA PvDBP_RII, which led to a 
boost as measured 4 weeks later on day 84 (Figure 4A) — this reached significance for group 2C versus 2A 
(Kruskal-Wallis test with Dunn’s multiple comparison test) (Figure 4C). Responses in group 2C (median 
15.6, range 10.5–27.2 ȝg/ml, n = 8) were also modestly, but significantly, higher than in group 2B (median 
Figure 2. Solicited AEs following vaccination with ChAd63 and MVA PvDBP_RII. The solicited local and systemic adverse events (AEs) recorded for 14 days 
following ChAd63 PvDBP_RII and for 7 days following MVA PvDBP_RII are shown at the maximum severity reported by all volunteers. (A) Four volunteers 
received 5 × 109 viral particles (vp) ChAd63 PvDBP_RII (group 1), and (B) 20 received 5 × 1010 vp (group 2). (C) Seven of the group 2 volunteers went on to 
receive MVA PvDBP_RII 1 × 108 PFU (group 2B), and (D) 8 received 2 × 108 PFU (group 2C). ChAd63, replication-deicient chimpanzee adenovirus serotype 63; 
MVA, modiied vaccinia virus Ankara; PvDBP_RII, region II of the P. vivax Dufy-binding protein.
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8.8, range 5.5–23.7 ȝg/ml, n = 8) at this peak time point (P = 0.014, Mann-Whitney test). Serum antibody 
responses decreased by day 140 but were well maintained above preboost levels, with no significant dif-
ference between groups 2B and 2C (P = 0.34, Mann-Whitney test) (Figure 4D). Day 84 plasma were also 
tested against a panel of  overlapping 20-mer linear peptides; however, few responses were detected above 
background, suggesting the vast majority of  vaccine-induced anti–PvDBP_RII IgG recognize conforma-
tional, as opposed to linear, epitopes (Supplemental Figure 5).
The serum antibody response against PvDBP_RII as measured by ELISA at day 84 was composed of  
IgG1 and modest levels of  IgG3 (Figure 4E), with little to no IgG2, IgG4, IgA, or IgM detectable above 
baseline (day 0) levels (Supplemental Figure 6). The avidity of  the anti–PvDBP_RII IgG, as measured by 
a NaSCN-displacement ELISA, was similar at day 84 for all volunteers in groups 2B and 2C, with the IC
50
 
ranging from 1.9 to 4.1 M. Avidity could only be measured for 1 vaccinee in group 2A at this time point 
with an IC
50
 of  2.8 M, suggesting no change following MVA PvDBP_RII boost (Figure 4F).
Previous studies have shown that antibody-secreting cells (ASCs) can be detected in peripheral blood 
for a short time (around day 7) after MVA boost when using the ChAd63-MVA regimen (41, 42). PvDBP_
RII–specific ASC responses were assessed by ex-vivo ELISPOT using frozen PBMCs collected at the day 
63 visit for volunteers in groups 2B and 2C. Median responses of  49 versus 159 ASCs per million PBMCs 
were observed, respectively, but there was no significant difference between the 2 groups (P = 0.69, Mann-
Whitney test) (Figure 5A). ASC responses across both groups showed a trend to associate with peak 
serum antibody responses at day 84, but this did not reach significance (Figure 5B).
Memory B cell (mBC) responses were also measured using an established cultured ELISPOT proto-
col, whereby mBCs within PBMCs undergo a 6-day polyclonal stimulation to form ASCs, which are then 
Figure 3. Ex-vivo IFN-Ȗ T cell response to vaccination. (A) Median ex vivo IFN-Ȗ ELISPOT responses in peripheral blood mononuclear cells (PBMCs) to 
the PvDBP_RII insert (summed response across all the individual peptide pools) shown for all groups. Individual responses are shown in Supplemen-
tal Figure 1. Median and individual responses are shown at (B) day 14, (C) day 63, and (D) day 140. Symbols are coded according to group. *P < 0.05. 
Responses between groups 1 (n = 4) and 2 (n = 20) at day 14, and between groups 2B (n = 7) and 2C (n = 8) at day 140 were assessed by Mann-Whitney 
test (B and D); responses between groups 2A (n = 4), 2B (n = 7), and 2C (n = 8) at day 63 were assessed by Kruskal-Wallis test with Dunn’s multiple 
comparison test (C). SFU, spot-forming units; PvDBP_RII, region II of the P. vivax Dufy-binding protein.
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measured using the same protocol as for the ex vivo assay. These were measured for volunteers in groups 
2B and 2C at the day 84 time point (4 weeks after MVA boost) — most consistently identified as the peak 
of  the mBC response in other trials of  ChAd63-MVA P. falciparum blood-stage malaria vaccines (41, 42). 
Responses are reported as number of  mBC-derived PvDBP_RII–specific ASCs per million cultured PBMCs 
(Figure 5C), and as a percentage of  total IgG-secreting ASCs (Figure 5D); in both cases these were sig-
nificantly higher in group 2C than 2B (Mann-Whitney test). These mBC responses across both groups also 
significantly correlated with peak serum antibody responses at day 84 (Figure 5, E and F).
Figure 4. Serum antibody response to vaccination. (A) Median anti–PvDBP_RII serum total IgG responses shown for all groups over time. Individual 
responses are shown in Supplemental Figure 3. Median and individual responses are shown at (B) day 28, (C) day 84, and (D) day 140. The horizontal dotted 
line indicates the limit of detection of the assay. (E) Isotype proiles of serum antibody responses were assessed by ELISA. Responses are shown at baseline 
(d0) and for all groups at day 84. Individual and median responses are shown for IgG1 and IgG3; results for IgG2, IgG4, IgA, and IgM are shown in Supplemen-
tal Figure 6. (F) Avidity of serum IgG responses at day 84 was assessed by NaSCN-displacement PvDBP_RII ELISA and is reported as the molar (M) concen-
tration of NaSCN required to reduce the starting OD in the ELISA by 50% (IC
50
). Symbols are coded according to group. *P < 0.05, **P < 0.01. Responses in 
groups 2A (n = 4), 2B (n = 7), and 2C (n = 8) were assessed by Kruskal-Wallis test with Dunn’s multiple comparison test; responses between groups 2B and 2C 
were assessed by Mann-Whitney test (C). PvDBP_RII, region II of the P. vivax Dufy-binding protein.
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Figure 5. B cell response to vaccination. (A) PvDBP_RII–specific antibody-secreting cell (ASC) responses were assessed by ex-vivo ELISPOT using 
PvDBP_RII protein and frozen peripheral blood mononuclear cells (PBMCs) from the day 63 time point. Individual and median responses are 
shown for each group and reported as PvDBP_RII–specific ASCs per million PBMCs used in the assay. (B) Correlation of the ASC response versus 
the concentration of serum anti–PvDBP_RII IgG measured at day 84. (C) PvDBP_RII–specific memory B cell (mBC) responses were assessed by 
ELISPOT assay using PvDBP_RII protein. Frozen PBMCs were thawed and underwent a 6-day polyclonal restimulation during which ASCs were 
derived from mBCs, before testing in the assay. Individual and median responses are shown from the day 84 time point and are reported as mBC-
derived PvDBP_RII–specific ASCs per million cultured PBMCs or as (D) percentage of total number of IgG-secreting ASCs. (E and F) Correlations of 
the mBC response versus the concentration of serum anti–PvDBP_RII IgG at day 84. For all correlations, Spearman’s rank correlation coefficient 
(r
s
) and P value are shown. *P < 0.05. Responses between groups 2B (n = 7) and 2C (n = 8) were assessed by Mann-Whitney test. PvDBP_RII, 
region II of the P. vivax Duffy-binding protein.
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Vaccine-induced antibodies inhibit PvDBP_RII-DARC binding in vitro. We next assessed the ability of vaccine-
induced serum IgG to inhibit binding of recombinant vaccine-homologous PvDBP_RII (SalI) to its receptor 
(in this case the recombinant N-terminal region of DARC), using an in vitro ELISA methodology in Oxford. 
Day 84 sera were tested using a 2-fold dilution series starting at 1:5 and through to 1:640, with percentage bind-
ing inhibition calculated for each volunteer using their matched day 0 serum sample as the baseline control. 
Example binding-inhibition curves are shown (Supplemental Figure 7A), and 50% binding-inhibition titers 
were interpolated from these data (Figure 6A). One sample in group 2A showed a weak 50% binding-inhibition 
titer of 1:16. All samples from groups 2B and 2C showed binding inhibition with median 50% titers of 1:137 
(range 1:14–1:248) and 1:168 (range 1:52–1:352), respectively. To further assess the quality of the vaccine-
induced antibody response, these titers were used to calculate the concentration of anti–PvDBP_RII polyclonal 
IgG that gives 50% binding inhibition in each individual (Figure 6B). Across all groups, the median levels were 
comparable, requiring 128, 96, and 105 ng/ml in groups 2A, 2B, and 2C, respectively. However, there was over 
a 10-fold range across all 16 individuals, with the best responder (in group 2C) only requiring 39 ng/ml, versus 
the worst responder requiring 540 ng/ml (in group 2B). These data suggest that interindividual qualitative 
differences exist in terms of the binding-inhibitory capacity of the polyclonal vaccine–induced IgG response.
Given that naturally acquired binding-inhibitory anti–PvDBP_RII antibodies can be strain specific (43, 
44), we next proceeded to test the day 0 and 84 sera from group 2 against an established panel of  recom-
binant PvDBP_RII alleles (Table 1) using methodology developed at ICGEB, India (Figure 6, C–F). No 
binding inhibition was observed for any of  the day 0 samples against any PvDBP_RII variant. Data for 
the SalI variant showed very similar results to those observed with the Oxford assay (Spearman’s correla-
tion r
s
 = 0.67, P = 0.002, n = 19). Day 84 sera also showed similar 50% binding-inhibition profiles for the 
3 other variants of  PvDBP_RII (PvAH, PvO, and PvP), with the same sample positive in group 2A, and 
median 50% binding-inhibition titers greater than 1:100 for both groups 2B and 2C for all test variants. At 
the individual level, all samples showed binding inhibition against each variant of  PvDBP_RII, but the 
50% binding-inhibition titers were variable, again consistent with qualitative differences in each polyclonal 
response (Supplemental Figure 7B). Interestingly, the individual titers were frequently highest against the 
vaccine-heterologous PvAH or PvO alleles.
Finally we tested the day 84 sera against an allele of  PvDBP_RII present in the HMP013 Indian strain 
of  P. vivax, which has recently been cryobanked for use as an inoculum in blood-stage CHMI clinical trials 
(16). After generating a draft assembly of  HMP013 (see supplementary material), analysis of  the PvDBP_
RII sequence from this strain (Table 1) revealed 10 polymorphic positions, of  which 5 were not shared with 
the other variants tested in this study, including some in subdomain 2 (SD2) close to the site shown to bind 
to aa 19–30 of  DARC (Figure 7A). Recombinant PvDBP_RII (HMP013) was subsequently generated and 
used in the Oxford assay. Binding-inhibition curves were similar to those previously observed with the SalI 
allele (Figure 7B). Fifty percent binding-inhibition titers were interpolated (Figure 7C), with the data for 
group 2 again showing a similar profile to those observed with the SalI variant (Figure 7D).
Discussion
This phase Ia dose-escalation and safety study reports the first data in humans for a vaccine targeting the 
PvDBP_RII antigen from the blood-stage P. vivax malaria parasite. We have shown in healthy malaria-naive 
Table 1. Sequence polymorphisms of PvDBP_RII variants
AA 
residue
261 263 288 326 330 339 340 341 345 353 359 372 379 392 402 A 458 464
SalI F R L K N D E K R S T N L W S – I E
P . S F . D G K N H . . K I R . . K .
O . S . . . G . . H . . . I . K . . .
AH . S . E . G . Q . . . K I R . . K .
HMP013 L S . . . G K N . T R . I . . L . K
The Salvador I (SalI) reference sequence is shown in bold. Amino acid polymorphisms are indicated for the region II of the P. vivax Duffy-binding protein 
(PvDBP_RII) variants (P, O, and AH) described previously (60), plus the P. vivax HMP013 strain. Amino acids that are the same as the reference sequence are 
indicated by a period, and a hyphen indicates an insertion/deletion. AHMP013 has a leucine insertion between V429 and P430 in the SalI reference sequence.
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Figure 6. PvDBP_RII–DARC in vitro binding inhibition. (A) Day 84 sera from volunteers in groups 1 (n = 4), 2A (n = 4), 2B (n = 7), and 2C (n = 8) were tested 
for their ability to inhibit binding of recombinant PvDBP_RII (SalI) to the Dufy antigen receptor for chemokines (DARC) using an ELISA-based assay in 
Oxford. Samples were titrated starting at 1:5 dilution down to 1:640 (Supplemental Figure 7A). Data show the interpolated dilution for each sample that 
gave 50% binding inhibition. (B) For positive samples in A (n = 16), the concentration of anti–PvDBP_RII (SalI) serum IgG that gives 50% binding inhibi-
tion (EC
50
) was calculated by dividing the serum ELISA ȝg/ml by the 50% binding-inhibition serum titer. The result is reported in ng/ml. (C–F) Day 0 and 
day 84 sera were assessed as in A using the assay established at ICGEB, India, using 4 recombinant alleles of PvDBP_RII: SalI, PvAH, PvO, and PvP. In all 
panels, the individual and median results are shown for each group. The dashed line shows an arbitrary cutof below which negative samples are plotted. 
PvDBP_RII, region II of the P. vivax Dufy-binding protein; SalI, Salvador I reference strain.
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adult volunteers that a recombinant ChAd63-MVA heterologous prime-boost immunization regimen can 
induce binding-inhibitory antigen-specific serum antibody responses in addition to B and T cell responses. 
ChAd63 and MVA recombinant for PvDBP_RII also demonstrated a favorable safety profile. Reactogenic-
ity of  the ChAd63 PvDBP_RII vector was similar to that seen consistently with the same doses of  ChAd63 
vectored vaccines encoding the P. falciparum pre-erythrocytic malaria antigens ME-TRAP or PfCSP (35, 
36) and the blood-stage antigens PfMSP1 or PfAMA1 (37, 38, 42, 45). In more recent years, safety and 
immunogenicity data for the ME-TRAP vaccines have been reported in adults, children, and infants residing 
in malaria-endemic areas (46). Our data with ChAd63 PvDBP_RII add to the growing body of  evidence 
that this simian adenovirus vector is safe for clinical use. Reactogenicity of  the MVA PvDBP_RII vector 
Figure 7. Binding inhibition of the P. vivax HMP013 strain DBP_RII. (A) The location of polymorphic residues in PvDBP_RII (HMP013 strain) have been 
marked on a structure of the PvDBP_RII (SalI strain) dimer bound to the Dufy antigen receptor for chemokines (DARC) aa 19–30 (PDB code 4NVU) (24). 
Two views of the dimer are shown, rotated by 90 degrees around the horizontal axis. One molecule of PvDBP_RII is shown in gray surface representation 
with polymorphic residues colored in red. The second molecule of PvDBP_RII is in blue cartoon representation with SD3 in a darker blue. The 2 helices 
from DARC are shown in green and cyan, respectively. (B) Day 84 sera from volunteers in groups 1 (n = 4), 2A (n = 4), 2B (n = 7), and 2C (n = 8) were tested 
for their ability to inhibit binding of recombinant PvDBP_RII (HMP013) to DARC using the ELISA-based assay in Oxford. Samples were titrated starting at 
1:5 dilution down to 1:640. Dashed line indicates 50% binding inhibition. Groups coded by color and symbol. (C) Data show the interpolated dilution for 
each sample that gave 50% binding inhibition. One sample in group 2B did not reach 50% binding inhibition by 1:640 dilution and is plotted at this inal 
titer with open triangle symbol. (D) Correlation of 50% binding-inhibition titers for the SalI and HMP013 alleles of PvDBP_RII measured using the assay in 
Oxford. Spearman’s rank correlation coeicient (r
s
) and P value are shown (n = 19). PvDBP_RII, region II of the P. vivax Dufy-binding protein.
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appeared to be more pronounced than the ChAd63 vector and increased with dose, again consistent with 
previous experience of  using this orthopoxvirus vector for P. falciparum vaccines (37, 38) as well as other 
disease targets such as respiratory syncytial virus (47), hepatitis C virus (48), Ebola virus (40), HIV, and 
Mycobacterium tuberculosis (49). Indeed, the clinical safety of  MVA as a recombinant vaccine vector for many 
infectious diseases and cancer is now well documented.
The ChAd63-MVA delivery platform was originally developed to induce T cell responses against a 
target blood-stage malaria antigen in humans (32, 33). Similar to our data in mice using this vaccine (27), 
the results presented here show that PvDBP_RII–specific IFN-Ȗ T cell responses were induced and peaked 
at median levels of  greater than 2,000 SFU/million PBMCs following the MVA boost. The kinetics and 
magnitude of  this response are extremely similar to those previously seen with the same vectors encoding 
P. falciparum antigens (35–38). These previous studies using the ChAd63-MVA regimen, as well as other 
studies using alternative ChAd serotypes followed by MVA boost (40, 47, 48), have routinely shown that a 
mixed antigen-specific CD4+/CD8+ T cell response is induced in humans.
The ELISPOT data showed that the IFN-Ȗ T cell responses were spread across all 6 peptide pools span-
ning the PvDBP_RII antigen. A previous study assessed IFN-Ȗ and IL-10 T cell responses to aa 291–460 
of  PvDBP_RII in naturally exposed children and adults from Papua New Guinea. These data showed that 
age-dependent low-level responses are detectable in a subset of  individuals following natural P. vivax infec-
tion (<150 SFU/million PBMCs using a 3-day cultured ELISPOT protocol, as opposed to the overnight 
stimulation used in the ex vivo assay reported here) (50). Five PvDBP_RII T cell epitopes were identified 
by peptide mapping, with 3 of  these containing polymorphic residues leading to variant-specific cellu-
lar responses (50). Nevertheless, the contribution of  T cell responses to blood-stage immunity against P. 
vivax remains unclear. In the case of  P. falciparum, clinical trials using whole-parasite immunization (51) or 
ChAd63-MVA vectors encoding PfMSP1 or PfAMA1 (45) failed to show an impact on blood-stage parasite 
growth following CHMI despite strong T cell induction by vaccination. However, recent data from other 
CHMI studies show that, unlike P. falciparum, blood-stage P. vivax activates cytotoxic CD38+ CD8+ T cells 
that could target parasites residing within MHC class I–expressing reticulocytes (52), suggesting that it may 
be possible for effector T cells to play a more direct role against this species of  human malaria parasite.
In agreement with preclinical data in mice and rabbits (27), the ChAd63-MVA prime-boost regimen 
also induced PvDBP_RII–specific serum IgG antibody responses, peaking at a median of  0.3 ȝg/ml after 
ChAd63 prime and 15.6 ȝg/ml after MVA boost in the full-dose vaccination groups. The kinetics and mag-
nitude of  the antigen-specific IgG, ASC, and mBC responses induced here in malaria-naive humans are 
consistent with those reported for the same vectors encoding the P. falciparum blood-stage antigens PfMSP1 
and PfAMA1 (37, 38, 41, 42). With regard to the PvDBP_RII–specific antibody concentrations, these were 
lower than those seen following ChAd63-MVA immunization with PfAMA1 (37, 42) and PfMSP1 (37), 
but 8-fold higher than with PfCSP (36). Similar to these P. falciparum vaccines (42, 53), the anti–PvDBP_
RII serum IgG response was largely composed of  IgG1 and some IgG3, with moderate avidity as measured 
by NaSCN-displacement ELISA. These qualitative aspects of  the vaccine-induced antibody responses are 
consistent with those observed to the same antigen following natural infection in endemic populations (54, 
55); however, the contributions of  antibody isotype, affinity, and avidity to protection against the P. vivax 
merozoite remain poorly understood.
Studies of  naturally acquired immunity following P. vivax exposure have reported the induction of  
strain-specific immunity (43, 44) and numerous sequence polymorphisms, consistent with immune eva-
sion, have been found within the PvDBP_RII antigen, with the majority localized to SD2 (24, 56). Never-
theless, high-titer naturally acquired BIAbs that block binding of  diverse PvDBP_RII alleles from P. vivax 
field isolates have also been reported, albeit at low frequency (30, 31). Once acquired, these antibodies are 
maintained and associate with clinical immunity to P. vivax. In contrast to these epidemiological data, 
preclinical immunogenicity studies with the SalI allele of  PvDBP_RII have shown that this immunogen is 
capable of  eliciting high-titer, cross-reactive BIAbs, as assessed using the ELISA-based binding-inhibition 
assay (28). Consistent with these data, our studies here suggest that PvDBP_RII vaccination of  humans can 
elicit antibodies that qualitatively differ from those induced by natural exposure. Across all vaccinees who 
received the ChAd63-MVA regimen, anti–PvDBP_RII responses were induced that blocked binding of  
variant PvDBP_RII alleles to DARC in vitro including one from the HMP013 strain, suggesting this strain 
would be suitable to test vaccine efficacy in a future phase IIa CHMI study (16). Encouragingly, median 
50% binding-inhibition titers greater than 1:100 were consistently observed for all test variants; these are 
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higher than the ~1:20 titers reported by others using a similar assay for naturally acquired, strain-transcend-
ing BIAbs in a limited number of  children in Papua New Guinea and associated with clinical immunity 
(30). However, this association with clinical immunity has never been formally demonstrated in the context 
of  a vaccine clinical trial. ChAd63-MVA PvDBP_RII is the first candidate vaccine against blood-stage P. 
vivax to reach clinical testing. It is therefore vital in a future CHMI efficacy study to assess whether vaccine-
induced BIAbs associate with control of  blood-stage parasite growth.
The data obtained from this study also suggested interindividual qualitative differences in terms of  
the polyclonal anti–PvDBP_RII IgG response, as would be anticipated following human vaccination. A 
recent cohort study in the Brazilian Amazon has suggested that genetic variation in HLA class II genes 
can influence antibody responses against PvDBP_RII following natural P. vivax infection (57). Similarly, 
studies of  naturally acquired anti–PvDBP_RII IgG responses (58) as well as mouse monoclonal antibod-
ies (59, 60) have reported linear and conformational epitopes. Here we failed to detect linear responses 
by ELISA using a peptide array, and our ongoing work will focus on elucidating epitopes recognized by 
vaccine-induced human B cells in order to guide future immuno-monitoring. Further ongoing work is 
seeking to assess antibody function against P. vivax parasites. Importantly, we have previously reported 
that adenovirus-MVA immunization of  mice and rabbits elicits antibodies that recognize native parasite 
antigen by immunofluorescence assay (IFA) (27). Future studies will focus on optimizing short-term 
invasion–inhibition assay methodology (61) to allow for functional testing of  vaccine-induced antibodies 
from human volunteers in clinical trials.
Overall, the association between Duffy negativity and protection against blood-stage P. vivax infection 
was first reported in 1976 (15), but until now this observation has not been translated into a clinical vac-
cine candidate. The intervening years have seen the PvDBP_RII–DARC interaction described in molecular 
detail and related immuno-epidemiology extensively studied in the field. Here we extend this work and 
demonstrate, possibly for the first time, that substantial PvDBP_RII–specific antibodies as well as B cell and 
T cell responses can be induced safely by immunization in humans, using a leading viral vectored delivery 
strategy that is in clinical development for numerous difficult and emerging diseases and cancer. Encourag-
ingly for the P. vivax vaccine field, a second PvDBP_RII protein–based vaccine formulated in the emulsified 
version of  glucopyranosyl lipid adjuvant (GLA-SE) has also recently entered a phase I clinical trial in India 
(CTRI/2016/09/007289). The demonstration in parallel of  a blood-stage CHMI model for vaccine testing 
using P. falciparum (62), and the banking of  similar blood-stage inocula for P. vivax (16), should allow for 
this ChAd63-MVA vaccine and others to progress to rapid phase IIa proof-of-concept efficacy testing in the 
near future.
Methods
Detailed methods are provided in supplemental methods.
ChAd63 and MVA PvDBP_RII vaccines. The design, production, and preclinical testing of  the viral 
vector vaccines have been reported previously (27). Briefly, both recombinant viruses express the same 
984-bp coding sequence of  PvDBP_RII from the SalI strain of  P. vivax, aa D194–T521 (GenBank Acces-
sion DQ156512). ChAd63 PvDBP_RII was manufactured under current Good Manufacturing Practice 
(cGMP) conditions by the Clinical Biomanufacturing Facility (CBF), University of  Oxford, UK, and MVA 
PvDBP_RII was manufactured under cGMP conditions by IDT Biologika GmbH, Germany, both as previ-
ously described (37).
Study design and approvals. The VAC051 study was a phase Ia open-label, dose-escalation, first-in-
human, nonrandomized trial of  the viral vectored vaccines ChAd63 PvDBP_RII and MVA PvDBP_RII 
given in a prime-boost regimen with an 8-week interval. The study was conducted at the Centre for Clinical 
Vaccinology and Tropical Medicine (CCVTM), University of  Oxford, Oxford, UK. The study received 
ethical approval from the Oxfordshire Research Ethics Committee A in Oxford, UK (REC reference 13/
SC/0001). The study was also reviewed and approved by the UK Medicines and Healthcare products Reg-
ulatory Agency (MHRA, reference 21584/0312/001-0001). Volunteers signed written consent forms and 
consent was verified before each vaccination. The trial was registered on Clinicaltrials.gov (NCT01816113) 
and was conducted according to the principles of  the current revision of  the Declaration of  Helsinki 2008 
and in full conformity with the ICH guidelines for Good Clinical Practice (GCP). The primary endpoint 
of  the study was to assess the safety of  ChAd63 PvDBP_RII and MVA PvDBP_RII, with a secondary 
endpoint to assess immunogenicity.
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Participants. Healthy, malaria-naive males and nonpregnant females aged 18–50 were invited to partici-
pate in the study. All volunteers were recruited and vaccinated at the CCVTM, part of  the Oxford Vaccine 
Centre (OVC), at the University of  Oxford. Twenty-four volunteers were enrolled in total. A full list of  
inclusion and exclusion criteria is reported in the supplemental methods.
Safety analysis. Data on AEs were collected throughout a volunteer’s participation in the trial, either on 
the diary cards they were issued with following vaccination or at follow-up visits. Any solicited AEs occur-
ring during the diary card period were defined as being at least possibly related to vaccination. The likely 
causality of  all other AEs was assessed as described in the protocol and all AEs considered possibly, prob-
ably, or definitely related to vaccination are reported (Supplemental Table 1). Further details on grading are 
provided in the supplemental material.
Peptides. Peptides for ex-vivo IFN-Ȗ ELISPOT were purchased from NEO Peptide (Supplemental Table 2), 
and for peptide ELISAs, biotinylated 20-mer peptides were synthesized by Mimotopes (Supplemental Table 3).
Recombinant PvDBP_RII and DARC proteins. Recombinant PvDBP_RII (SalI) protein for ELISA-based 
assays was generated using a Drosophila melanogaster Schneider 2 (S2) polyclonal stable cell line (ExpreS2 
platform, ExpreS2ion Biotechnologies) (63). Recombinant N-terminal DARC was produced for use in 
the PvDBP_RII–DARC binding-inhibition assay in Oxford, UK, by transient transfection of  suspension 
HEK293E cells grown in EXPI293 expression medium (Thermo Fisher Scientific) (34). For the HMP013 
strain of  P. vivax, the sequence of  the PvDBP_RII gene was verified by Sanger sequencing using prim-
ers listed in Supplemental Table 4, and recombinant PvDBP_RII (HMP013) produced in suspension 
EXPI293F cells (Thermo Fisher Scientific) by transient transfection.
Ex vivo IFN-Ȗ ELISPOT. Ex vivo IFN-Ȗ ELISPOT was used to assess the kinetics and magnitude of  
the vaccine-induced T cell responses over time. Fresh PBMCs were used in all assays using a previously 
described protocol (38). Results are expressed as IFN-Ȗ SFU per million PBMCs.
Total IgG ELISAs. ELISAs were performed using standardized methodology as previously described (37, 
38), except that plates were coated with recombinant PvDBP_RII protein produced from the Drosophila S2 
cells and blocked with StartingBlock T20 solution (Thermo Fisher Scientific). Responses measured in AU are 
reported in ȝg/ml following generation of a conversion factor by CFCA.
Avidity and isotype ELISAs. IgG antibody avidity was assessed by NaSCN-displacement ELISA using 
previously described methodology (53), except that plates were coated with recombinant PvDBP_RII pro-
duced from the Drosophila S2 cells at 2 ȝg/ml and blocked with StartingBlock T20 solution. The concentra-
tion of  NaSCN required to reduce the OD
405
 to 50% of  that without NaSCN was used as a measure of  avid-
ity (IC
50
). Antibody isotype ELISAs were also performed using methodology described in detail elsewhere 
(53) with the same exceptions as for the avidity ELISA.
mBC and ASC ELISPOT. mBC ELISPOT assays were performed as described in detail elsewhere (41). 
Ex vivo ASC ELISPOT assays were performed using frozen PBMCs directly prepared and added to the 
ELISPOT plate with no preceding 6-day culture.
PvDBP_RII–DARC binding-inhibition assay. Sera were tested for their ability to inhibit binding of  recom-
binant PvDBP_RII to DARC using an assay developed at Oxford, UK (Figure 6, A and B; Figure 7, B–D; 
and Supplemental Figure 7A). Sera were also tested using a similar assay previously established at ICGEB, 
India (64) (Figures 6, C–F and Supplemental Figure 7B). Four variants of  recombinant PvDBP_RII (SalI, 
PvAH, PvO, and PvP) were used.
Statistics. Data were analyzed using GraphPad Prism version 6.07 for Windows. All tests were 2-tailed 
and are described in the text. A value of  P less than 0.05 was considered significant.
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